Combining AI and Automation in the SynFini™ Platform to Accelerate Small Molecule Drug Discovery, Upcoming Webinar Hosted by Xtalks
In this free webinar, the featured speaker will discuss the SynFini platfrom, which combines multiple AI design and lab automation tools to create automated workflows in molecular chemistry discovery and development. The intelligent use of automation can rapidly fill gaps in both data volume and quality for improved AI-guided decision making. When suitably combined, AI and automation have the potential to greatly increase the speed and quality of R&D, while reducing the overall cost of molecular discovery and development.
TORONTO, May 28, 2021 /PRNewswire-PRWeb/ -- The rate of chemical discovery and development is hampered by the fact that chemistry is still inherently a manual process. In an effort to improve and accelerate the reproducibility and transferability of chemistry, we have developed an automation platform named SynFini™ that automates the design, reaction screening and optimization (RSO) and production of target molecules.
SynFini includes three core components. A computational tool, SynRoute, develops synthetic strategies for molecules of interest. A high throughput RSO platform, SynJet, enabled by inkjet printing uses statistical design of experiment (DoE) to validate these strategies. Automated analysis of the RSO results facilitates the preparation of digital synthesis protocols that can be downloaded to a bench top multistep synthesizer, called AutoSyn. AutoSyn is a flow chemistry workstation capable of performing synthesis routes at the milligram to gram scale while automatically capturing all synthesis parameters in real-time into a new automated chemistry reaction database.
To accelerate multi-parametric optimization in drug discovery, artificial intelligence (AI) can be included to aid in the design, selection and prioritization of target structures with desired properties, and can be interfaced with SynFini automated synthesis and bioassay testing for rapid 'design-make-test' cycles. We are also using the core SynFini components for process development to provide synthetic route and kinetic data to create 'digital twin' computer models of continuous manufacturing systems for APIs that enable direct translation of scale-up from bench to multi-kg/hr production in one step.
Register for this webinar to hear about how the SynFini tools work independently and then how they fit together into seamless AI-data driven automated solutions for drug discovery and process development are presented.
Join Nathan Collins, Chief Strategy Officer, SRI Biosciences, A Division of SRI International, for the live webinar on Wednesday, June 16, 2021 at 1pm EDT (10am PDT).
For more information, or to register for this event, visit Combining AI and Automation in the SynFini™ Platform to Accelerate Small Molecule Drug Discovery.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Ayesha Rashid, Xtalks, +1 (416) 977-6555 x 272, [email protected]
SOURCE Xtalks
Share this article